Oral JAK Inhibitor Promising in Ankylosing SpondylitisOral JAK Inhibitor Promising in Ankylosing Spondylitis

The first study to assess the safety and efficacy of tofacitinib in ankylosing spondylitis suggests that JAK inhibition might be a new way to achieve control in patients with active disease. Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Rheumatology News Source Type: news